Literature DB >> 11862319

Prostaglandins as inflammatory messengers across the blood-brain barrier.

David Engblom1, Monica Ek, Sipra Saha, Anders Ericsson-Dahlstrand, Per-Johan Jakobsson, Anders Blomqvist.   

Abstract

Upon immune challenge the brain launches a wide range of responses, such as fever, anorexia, and hyperalgesia that serve to maintain homeostasis. While these responses are adaptive during acute infections, they may be destructive during chronic inflammatory conditions. Research performed during the last decade has given us insight into how the brain monitors the presence of a peripheral inflammation and the mechanisms underlying the brain-mediated acute-phase reactions. Here we give a brief review on this subject, with focus on the role of prostaglandin E2 produced in cells associated with the blood-brain barrier in immune-to-brain signaling. The recent advances in this field have not only elucidated the mechanisms behind the anti-pyretic and anti-hyperalgesic effects of cyclooxygenase inhibitors, but have also identified novel and more-selective potential drug targets.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11862319     DOI: 10.1007/s00109-001-0289-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  32 in total

1.  Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice.

Authors:  Jon Lampa; Marie Westman; Diana Kadetoff; Anna Nordenstedt Agréus; Erwan Le Maître; Caroline Gillis-Haegerstrand; Magnus Andersson; Mohsen Khademi; Maripat Corr; Christina A Christianson; Ada Delaney; Tony L Yaksh; Eva Kosek; Camilla I Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

2.  The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.

Authors:  Alexandre A Steiner; Alla Y Molchanova; M Devrim Dogan; Shreya Patel; Erika Pétervári; Márta Balaskó; Samuel P Wanner; Justin Eales; Daniela L Oliveira; Narender R Gavva; M Camila Almeida; Miklós Székely; Andrej A Romanovsky
Journal:  J Physiol       Date:  2011-03-14       Impact factor: 5.182

3.  Neural controls of prostaglandin 2 pyrogenic, tachycardic, and anorexic actions are anatomically distributed.

Authors:  Karolina P Skibicka; Amber L Alhadeff; Theresa M Leichner; Harvey J Grill
Journal:  Endocrinology       Date:  2011-03-29       Impact factor: 4.736

4.  LC/MS/MS method for analysis of E₂ series prostaglandins and isoprostanes.

Authors:  Stephen A Brose; Brock T Thuen; Mikhail Y Golovko
Journal:  J Lipid Res       Date:  2011-02-10       Impact factor: 5.922

5.  Estradiol-induced antinociceptive responses on formalin-induced nociception are independent of COX and HPA activation.

Authors:  Deirtra A Hunter; Gordon A Barr; Nicole Amador; Kai-Yvonne Shivers; Lynne Kemen; Christopher M Kreiter; Shirzad Jenab; Charles E Inturrisi; Vanya Quinones-Jenab
Journal:  Synapse       Date:  2011-02-25       Impact factor: 2.562

6.  Prostaglandins mediate zymosan-induced sickness behavior in mice.

Authors:  Juliana B M Lima; Clarice C Veloso; Fabiana C Vilela; Alexandre Giusti-Paiva
Journal:  J Physiol Sci       Date:  2016-10-03       Impact factor: 2.781

Review 7.  Fetal inflammatory response and brain injury in the preterm newborn.

Authors:  Shadi Malaeb; Olaf Dammann
Journal:  J Child Neurol       Date:  2009-07-15       Impact factor: 1.987

8.  Mechanisms of brain signaling during sepsis.

Authors:  Najla Akrout; Tarek Sharshar; Djillali Annane
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 9.  Inflammatory Disequilibrium in Stroke.

Authors:  Danica Petrovic-Djergovic; Sascha N Goonewardena; David J Pinsky
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

10.  A fast one-step extraction and UPLC-MS/MS analysis for E2/D 2 series prostaglandins and isoprostanes.

Authors:  Stephen A Brose; Andrew G Baker; Mikhail Y Golovko
Journal:  Lipids       Date:  2013-02-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.